Stockscreener 앱 받기
59.33
0.27%
0.1537
전일 마감가:
$59.18
열려 있는:
$58.45
하루 거래량:
770.28K
Relative Volume:
0.22
시가총액:
$26.33B
수익:
$2.44B
순이익/손실:
$1.36B
주가수익비율:
31.08
EPS:
1.9093
순현금흐름:
$574.14M
1주 성능:
+0.54%
1개월 성능:
+5.83%
6개월 성능:
+42.37%
1년 성능:
+59.86%
1일 변동 폭
$58.45
$59.39
1주일 범위
$58.45
$60.44
52주 변동 폭
$34.08
$60.44
로열티 파마 Stock (RPRX) Company Profile
명칭
Royalty Pharma Plc
전화
(212) 883-0200
주소
110 EAST 59TH STREET, NEW YORK, NY
Compare RPRX vs VRTX, REGN, ARGX, RVMD, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
59.39 | 26.03B | 2.44B | 1.36B | 574.14M | 1.9093 |
VRTX
Vertex Pharmaceuticals Inc
|
475.40 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
706.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
860.71 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.96 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
320.81 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
로열티 파마 Stock (RPRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-30 | 업그레이드 | UBS | Neutral → Buy |
| 2025-09-30 | 개시 | Goldman | Buy |
| 2025-05-16 | 개시 | Morgan Stanley | Overweight |
| 2024-06-03 | 다운그레이드 | UBS | Buy → Neutral |
| 2022-06-14 | 재개 | UBS | Buy |
| 2022-05-13 | 개시 | Scotiabank | Sector Outperform |
| 2022-04-27 | 개시 | Goldman | Buy |
| 2022-04-14 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2022-04-06 | 재개 | Morgan Stanley | Overweight |
| 2021-10-29 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-07-30 | 개시 | Tigress Financial | Buy |
| 2020-11-09 | 업그레이드 | UBS | Neutral → Buy |
| 2020-07-14 | 개시 | Evercore ISI | In-line |
| 2020-07-13 | 개시 | BofA Securities | Buy |
| 2020-07-13 | 개시 | Citigroup | Neutral |
| 2020-07-13 | 개시 | Cowen | Outperform |
| 2020-07-13 | 개시 | Goldman | Neutral |
| 2020-07-13 | 개시 | JP Morgan | Neutral |
| 2020-07-13 | 개시 | Morgan Stanley | Equal-Weight |
| 2020-07-13 | 개시 | SunTrust | Buy |
| 2020-07-13 | 개시 | UBS | Neutral |
모두보기
로열티 파마 주식(RPRX)의 최신 뉴스
Royalty Pharma stock hits all-time high at 59.73 USD - Investing.com
Renaissance Technologies LLC Buys Shares of 790,937 Royalty Pharma PLC $RPRX - MarketBeat
First Trust Advisors LP Reduces Holdings in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma PLC (RPRX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Daily Brief Health Care: Apnimed, Chugai Pharmaceutical, Equifax Inc, Royalty Pharma , Startline, Surgery Partners, Teva Pharmaceutical Sp Adr, Thermo Fisher Scientific Inc and more - Smartkarma
Current ratio of Royalty Pharma Plc Class A – HAM:RPD - TradingView
Royalty Pharma Plc Class A Revenue Breakdown – HAM:RPD - TradingView
Royalty Pharma PLC (RPRX) Cash Flow - TradingKey
Royalty Pharma PLC (RPRX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Royalty Pharma PLC (RPRX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
RPRX|Royalty Pharma PLC|Price:58.730|Chg%:-0.100 - TradingKey
Royalty Pharma PLC (RPRXN) Q4 2022 Earnings ReportResults, Call & Slides - TipRanks
Dai ichi Life Insurance Company Ltd Has $6.19 Million Stock Position in Royalty Pharma PLC $RPRX - MarketBeat
Dorsey Asset Management LLC Raises Stock Position in Royalty Pharma PLC $RPRX - MarketBeat
Arrowstreet Capital Limited Partnership Lowers Position in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma PLC (RPRXN) Q2 2023 Earnings ReportResults, Call & Slides - TipRanks
Royalty Pharma Plc Class A Revenue Breakdown – TRADEGATE:RPD - TradingView
Royalty Pharma PLC (RPRXN) Q3 2023 Earnings ReportResults, Call & Slides - TipRanks
Royalty Pharma PLC $RPRX Shares Sold by KBC Group NV - MarketBeat
RPHC5035520 Bond Profile — Key Metrics - TradingView
ABN Amro Investment Solutions Purchases New Shares in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma PLC (RPRXN) Q4 2025 Earnings ReportResults, Call & Slides - TipRanks
Royalty Pharma PLC (RPRXN) Q3 2025 Earnings ReportResults, Call & Slides - TipRanks
Royalty Pharma PLC (RPRXN) Q2 2025 Earnings ReportResults, Call & Slides - TipRanks
Royalty Pharma PLC (RPRXN) Q4 2023 Earnings ReportResults, Call & Slides - TipRanks
Royalty Pharma PLC (RPRXN) Q1 2025 Earnings ReportResults, Call & Slides - TipRanks
Royalty Pharma PLC (RPRX) Q4 2024 Earnings ReportResults, Call & Slides - TipRanks
Royalty Pharma PLC (RPRXN) Q1 2024 Earnings ReportResults, Call & Slides - TipRanks
Royalty Pharma PLC (RPRXN) Q4 2024 Earnings ReportResults, Call & Slides - TipRanks
Royalty Pharma PLC (RPRXN) Q1 2026 Earnings ReportResults, Call & Slides - TipRanks
Royalty Pharma PLC (RPRXN) Q2 2024 Earnings ReportResults, Call & Slides - TipRanks
Royalty Pharma PLC (RPRXN) Earnings Dates, Call Summary & Reports - TipRanks
RPHC6166014 Bond Profile — Key Metrics - TradingView
Royalty Pharma PLC (RPRX) Q4 2022 Earnings ReportResults, Call & Slides - TipRanks
Inceptionr LLC Increases Stock Holdings in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma plc (RPRX) Stock Price, News, Quote & History - Yahoo! Finance Canada
CI Investments Inc. Has $8.33 Million Stock Holdings in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma PLC (RPRX) Q1 2026 Earnings ReportResults, Call & Slides - TipRanks
Royalty Pharma PLC (RPRX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
RPHC5222528 Bond Profile — Key Metrics - TradingView
RPHC6166014 Bond Coupon Profile — Rate & Payments - TradingView
RPHC5035520 Bond Risk Profile - TradingView
Royalty Pharma plc (RPRX) stock price, news, quote and history - Yahoo Finance UK
RPHC5237354 Bond Coupon Profile — Rate & Payments - TradingView
RPHC5237354 Bond Risk Profile - TradingView
Royalty Pharma (NASDAQ:RPRX) Reaches New 1-Year HighShould You Buy? - MarketBeat
RPHC5237354 Bond Profile — Key Metrics - TradingView
RPHC5035520 Bond Coupon Profile — Rate & Payments - TradingView
Neurimmune sells a portion of its royalty interest in cliramitug to Royalty Pharma - marketscreener.com
Royalty Pharma PLC (RPRX) Q2 2023 Earnings ReportResults, Call & Slides - TipRanks
Bank of New York Mellon Corp Reduces Stock Position in Royalty Pharma PLC $RPRX - MarketBeat
로열티 파마 (RPRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
로열티 파마 주식 (RPRX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Hite Christopher | EVP & Chairman, Partnering |
Jun 30 '26 |
Sale |
56.52 |
100,000 |
5,651,813 |
459,399 |
| Hite Christopher | EVP & Chairman, Partnering |
Jun 30 '26 |
Sale |
56.46 |
30,000 |
1,693,658 |
40,000 |
0.92%
1.17%
자본화:
|
볼륨(24시간):